Mark Robinson

The Anglo-Dutch group has reduced net debt markedly from pre-pandemic levels

The data analytics group continues to expand its global footprint and product offering

The biotech firm has awarded another special dividend

The car dealer is navigating supply-side issues and wider labour shortages

The World Health Organization gives the green light

The lighting specialist has had to contend with a range of challenges

It would be overly optimistic to rule out further government lockdowns

Following restructuring measures, the group is in better trim to take advantage of a bounce-back in its end-markets

If you failed to capture the earnings growth generated by the mRNA vaccine candidates, there are new therapies in the trial phase

The veterinary pharma group has been boosted by rising Southern European demand